Palisade Bio

Palisade Bio Palisade Bio (Nasdaq: PALI) is advancing next-generation oral PDE4 inhibitor prodrugs for inflammatory and fibrotic diseases.

05/19/2026

Today is , a global movement to stand with the millions of people living with Ulcerative Colitis and Crohn's disease worldwide.

Ulcerative Colitis and Crohn's disease are chronic conditions where many patients face relapsing inflammation, loss of treatment response, and in some cases irreversible bowel damage, despite approved existing therapies.

That's the gap we're working to close.

Palisade's lead program, PALI-2108, is a once-daily oral PDE4 inhibitor prodrug designed to be selectively bioactivated in the ileum and colon, initiating targeted PDE4 inhibition at sites of disease while enabling systemic distribution of the active drug. PALI-2108 is being developed for the potential treatment of Ulcerative Colitis and Crohn's disease.

Learn about our pipeline: https://bit.ly/3P9Ou84

05/13/2026

“We continue to see a consistent and differentiated profile emerging for PALI-2108 across IBD,” said JD Finley, Chief Executive Officer of Palisade Bio. Palisade plans to advance into Phase 2 development of PALI-2108 in both ulcerative colitis and Crohn’s disease. For recent highlights and anticipated milestones, visit: https://bit.ly/4u1XhrC

05/12/2026

Palisade today reported financial results for the first quarter ended March 31, 2026 and highlighted continued clinical advancements of its lead program, PALI-2108, including recent data readouts and anticipated Phase 2 trial initiations. For details: https://bit.ly/4u1XhrC

05/06/2026

Additional steady-state pharmacokinetic findings provide mechanistic support for previously reported PALI-2108 Phase 1b clinical activity and support PALI-2108’s potential as a once-daily, gut-targeted oral therapy. More info: https://bit.ly/4ng0n94

05/05/2026

“These additional pharmacokinetic and translational analyses further characterize the differentiated profile of PALI-2108," said Mitch Jones, MD, Ph.D., President & Chief Medical Officer of Palisade Bio. Read More: https://bit.ly/4ng0n94

05/05/2026

PALI-2108 Phase 1a/b data presented at Digestive Disease Week 2026 demonstrate colon tissue PDE4/cAMP pathway modulation and sustained active metabolite exposure above IC90 across the dosing interval, highlighting a differentiated profile. Learn more: https://bit.ly/4ng0n94

05/05/2026

Palisade today announced the presentation of additional Phase 1a/b analyses of PALI-2108, including delayed ileocolonic activation, high tissue-to-plasma exposure, and sustained steady-state concentrations of the active metabolite (PALI-0008) above IC90, at Digestive Disease Week 2026, further characterizing the pharmacokinetic and translational profile of the program. For details: https://bit.ly/4ng0n94

05/04/2026

Attending Digestive Disease Week® (DDW) 2026? Data from Palisade's lead program, PALI-2108, will be presented tomorrow, May 5th from 12:30-1:30 PM CDT. Learn more: https://bit.ly/4tRoTPR

04/28/2026

Data from Palisade's lead program, PALI-2108, will be presented at Digestive Disease Week® (DDW) 2026 on Tuesday, May 5th from 12:30-1:30 PM CDT. For poster presentation details: https://bit.ly/4tRoTPR

04/16/2026

Tune-in today, April 16th at 2:15 PM ET for a presentation from JD Finley, Chief Executive Officer, and Dr. Mitchell Jones, President and Chief Medical Officer of Palisade Bio, at the Needham & Co. 25th Annual Healthcare Conference: https://bit.ly/3PTHzji

04/16/2026

Palisade Bio today announced that data from its lead program, PALI-2108, has been selected for poster presentation at Digestive Disease Week® (DDW) 2026, taking place May 2–5, 2026 in Chicago. For details: https://bit.ly/4tRoTPR

Address

5800 Armada Drive, Suite 210
Carlsbad, CA
92008

Telephone

+18587044900

Website

Alerts

Be the first to know and let us send you an email when Palisade Bio posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Palisade Bio:

Shortcuts

Share

Category